Detecting Irreversible Cervical Cancer via E6/p53 Protein Complexes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting cervical cancer in the uterine cervix lack specificity in identifying irreversible neoplastic transformation, leading to over-diagnosis and over-treatment, particularly in young women, and there is a need for biomarkers that indicate the progression from precancerous lesions to cancer.
Innovation Solution
The method involves analyzing the interaction between HPV oncogenes E6 and E7 with host cell tumor suppressor genes p53 and pRb using Western Blot and Sandwich ELISA techniques to detect protein complexes E6/p53 and E7/pRb, which indicate irreversible neoplastic transformation, thereby enhancing diagnostic accuracy and reducing over-diagnosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current screening methods (Pap test and hr-HPV DNA testing) are used to detect cervical cancer, then the sensitivity of detecting precancerous lesions is improved, but the specificity for identifying irreversible neoplastic transformation deteriorates, leading to over-diagnosis and over-treatment
Solution Approach 1:
The invention segments the detection process into multiple stages: first detecting HPV DNA presence, then analyzing specific protein interactions (E6-p53 and E7-pRb complexes) to determine irreversibility. This segmentation allows each stage to address specific aspects of the diagnostic challenge, improving overall precision without sacrificing sensitivity.
Solution Approach 2:
The invention introduces protein interaction analysis as an intermediary step between HPV DNA detection and final diagnosis. By detecting the presence of specific protein complexes (E6-p53 and E7-pRb), the method provides additional information about the irreversibility of neoplastic transformation, thereby improving specificity while maintaining the initial sensitivity gain from HPV testing.
2Reliability
If screening tests are performed to identify all potential cases, then the sensitivity increases, but the number of false positives increases, resulting in unnecessary treatments
Solution Approach 1:
The invention implements a feedback mechanism where the results of protein interaction analysis (E6-p53 and E7-pRb complexes) feed back into the diagnostic decision-making process. This feedback allows clinicians to distinguish between reversible and irreversible lesions, reducing false positives and preventing unnecessary treatments while maintaining high sensitivity for detecting true cases.
Solution Approach 2:
Protein interaction analysis serves as an intermediary triage step that filters out false positives from HPV DNA testing. By introducing this additional layer of analysis, the method reduces over-diagnosis and over-treatment while preserving the sensitivity benefits of comprehensive screening.
3Device complexity
If only HPV DNA testing is performed, then the simplicity and cost-effectiveness are maintained, but the ability to distinguish reversible from irreversible lesions is insufficient
Solution Approach 1:
The invention segments the diagnostic approach into a simple initial HPV DNA test followed by a more specific protein interaction analysis only when needed. This segmentation maintains simplicity for routine screening while providing enhanced precision for cases requiring further evaluation, balancing complexity and diagnostic accuracy.
Solution Approach 2:
The invention performs preliminary HPV DNA testing to identify candidates who may require further analysis. This preliminary action filters the population, allowing resource-intensive protein interaction analysis to be applied only to those who need it, thereby maintaining overall cost-effectiveness while improving the detection of irreversible lesions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach increases the sensitivity and specificity of cervical cancer screening by identifying irreversible carcinogenesis, reducing unnecessary treatments and improving the predictive value of screening tests.
Implementation Method 1
The detection being performed by the combined use of antibodies anti-protein E6 and antibodies anti-protein E7 and of antibodies anti-protein p53 and antibodies anti-protein pRb, preferably in Western Blot or Sandwich ELISA analytic techniques
Implementation Method 2
identifying the presence of a protein complex E6/p53 made by the protein E6 with the protein p53 and/or a protein complex E7/pRb made by the protein E7 with the protein pRb
Implementation Method 3
The detection being performed by the combined use of antibodies anti-protein E6 and antibodies anti-protein E7 and of antibodies anti-protein p53 and antibodies anti-protein pRb, preferably in Western Blot or Sandwich ELISA analytic techniques
Data Source
Figure 1~2
Figure 3~6
Figure 7
AI summary
The invention concerns some methods for diagnosing cancer of the uterine cervix (or extra-uterine) which integrate or surrogate the field of action of cytology with that of molecular biology, and provide a system for diagnosis, prognosis and management of HPV-induced cervical lesions (or extra-uterine) which exploit, in particular, the analytical methods of Western Blot and Sandwich ELISA in order to detect those cases where the transformation towards a neoplastic lesion has become irreversible. The methods consist in detecting, in samples of cells taken from the squamous-columnar junction of the uterine cervix of a patient under examination, the proteins encoded by viral oncogenes E6 and E7 and those encoded by the tumor suppressor genes of the host cell p53 and pRB, and in detecting by Western Blot and/or by Sandwich ELISA the possible interaction between proteins E6 and p53, and between proteins E7 and pRb, as an index of irreversible transformation towards a neoplastic lesion.